Pricing and reimbursement mechanisms for advanced therapy medicinal products in 20 countries [PDF]
Frontiers in Pharmacology, 2023 Introduction: Advanced Therapy Medicinal Products are a type of therapies that, in some cases, hold great potential for patients without an effective current therapeutic approach but they also present multiple challenges to payers.
Juan Carlos Rejon-Parrilla +7 more
doaj +7 more sources
The effects of reimbursement mechanisms on medical technology diffusion in the hospital sector in the Italian NHS [PDF]
Health Policy, 2014 The aim of this study was to investigate how the differences across the regional reimbursement mechanisms and in particular the use of the DRGs impact on the level in the high technology equipment diffusion.Based on hospital sector data at a regional level we build up indicators to measure the regional diffusion of high technological medical equipment ...
Massimo Finocchiaro Castro +2 more
exaly +5 more sources
Journal of Health Economics and Outcomes Research, 2023 # Background Value-based reimbursement strategies have been considered in the continuous search for establishing a sustainable healthcare system. For models that have been already implemented, success is demonstrated according to specific details of the ...
Ana Paula Beck de Silva Etges +3 more
doaj +3 more sources
Primary versus revision total shoulder arthroplasty: comparing relative value and reimbursement trends [PDF]
Clinics in Shoulder and Elbow, 2022 Background Total shoulder arthroplasty (TSA) has been demonstrated to be an effective treatment for multiple shoulder pathologies. The purpose of our study was to compare the relative value units (RVUs) per minute of surgical time for primary and ...
John Joseph Carney +6 more
doaj +1 more source
How Denmark, England, Estonia, France, Germany, and the USA Pay for Variable, Specialized and Low Volume Care: A Cross-country Comparison of In-patient Payment Systems [PDF]
International Journal of Health Policy and Management, 2022 Background Diagnosis-related group (DRG)-based hospital payment can potentially be inadequately low (or high) for highly variable, highly specialized, and/or low volume care.
Wilm Quentin +7 more
doaj +1 more source
Rationale for Establishing a Mechanism to Increase Reimbursement to Hypertension Specialists [PDF]
The Journal of Clinical Hypertension, 2013 Hypertension is an important public health problem both in the United States and worldwide, contributing to many forms of cardiovascular and renal diseases. Although great strides have been made in the proportion of the US population that achieves recommended blood pressure targets, many Americans still have undertreated and uncontrolled blood pressure
William J, Elliott +5 more
openaire +2 more sources
Effect of retirement on medical reimbursement expenses—evidence from China
Health Economics Review, 2023 Background Medical reimbursement in China is not for all diseases, and medical reimbursement expenses are not completely consistent with medical service demand, though the scope and proportion of medical reimbursement are gradually expanding.
Yuanyang Wu, Jiahui Pang, Hualei Yang
doaj +1 more source
Cancer Medicine, 2020 Objectives Value‐based pricing of oncology drugs provides a best estimate for the price of a drug, as it relates to the benefits it provides for individual patients. To date, the impact of value‐based pricing to reference cost‐effectiveness thresholds (λ)
Ambica Parmar +3 more
doaj +1 more source
Incentives to transfer patients under alternative reimbursement mechanisms [PDF]
Journal of Public Economics, 1988 Alternative hospital reimbursement systems may influence the frequency and timing of patient transfers between hospitals as well as the patient's length of stay. This paper examines the characteristics of reimbursement systems that result in efficient and equitable transfers and efficient lengths of stay.
Randall P. Ellis, Christopher J. Ruhm
openaire +1 more source
Analysis of changes in drug reimbursement based on the example of the limit groups containing beta-2 adrenergic drugs in Poland in the years 2012-2021 [PDF]
Farmacja Polska, 2022 Subject of the study The subject of the study is a price analysis of the limit groups of reimbursed beta-2 adrenergic drugs. Rationalisation of reimbursement expenditure, including generic substitution, is carried out in order to maximise health effects ...
Piotr Zbigniew Rykowski +3 more
doaj +1 more source